Hyperbaric Oxygen Therapy (HBOT) in Cancer Care: Science, Benefits, and Best Practices

14 Mar

For decades, Hyperbaric Oxygen Therapy (HBOT) has been used to accelerate wound healing, treat decompression sickness, and address conditions like carbon monoxide poisoning. But in recent years, its role in cancer care has gained increasing attention. From reducing chemotherapy side effects to enhancing recovery and supporting metabolic cancer therapies, HBOT is becoming a valuable tool in the world of integrative oncology.

But what does the science say? How does HBOT work in the context of cancer care? And what should patients look for when considering this therapy?

In this deep dive, we’ll explore the history of HBOT in cancer care, the mechanisms behind its effectiveness, how it fits into metabolic oncology strategies, and what to watch for when seeking treatment.

The History of HBOT in Cancer Treatment

HBOT has been used in medicine for over 350 years, but its application in cancer care is relatively new. Originally, hyperbaric chambers were developed for treating deep-sea divers suffering from decompression sickness (the bends). Over time, researchers discovered that increasing oxygen levels in the body had far-reaching effects, including improved wound healing, reduced inflammation, and enhanced immune function.

In the 1960s and 70s, researchers began to explore HBOT’s impact on tumor biology and radiation damage. While early studies showed mixed results, modern research is now uncovering clear mechanisms that demonstrate its potential in oncology.

Today, HBOT is widely recognized for its role in treating radiation-induced tissue damage, enhancing post-surgical healing, and supporting the metabolic treatment of cancer when used strategically within an integrative approach.

How HBOT Works in Cancer Care

At its core, HBOT works by increasing the oxygen concentration in the body. Inside a hyperbaric chamber, a patient breathes in 100% oxygen while exposed to increased atmospheric pressure (typically between 2.0 to 3.0 ATA) for 60-90 minutes per session.

This process results in:

Increased oxygen levels in blood plasma – Oxygen dissolves directly into the plasma, allowing it to reach areas with poor circulation, including hypoxic (low-oxygen) tumor environments.
Reduced tumor hypoxia – Many cancer cells thrive in low-oxygen (hypoxic) environments, where they become more aggressive and resistant to treatment. HBOT reverses this hypoxia, making tumors more vulnerable to therapies like radiation, chemotherapy, and metabolic interventions.
Enhanced immune response – Higher oxygen levels stimulate immune activity, particularly by activating macrophages and natural killer cells, which are crucial in targeting cancer cells.
Angiogenesis & Tissue Repair – HBOT promotes the formation of new blood vessels, improves wound healing after surgery, and repairs radiation-damaged tissues.

The Role of HBOT in Metabolic Oncology & the Press-Pulse Strategy

One of the most exciting areas of research is HBOT’s role in integrative metabolic oncology, particularly in conjunction with the Press-Pulse strategy.

The “Press” Phase: This phase involves creating a hostile metabolic environment for cancer cells by restricting their primary fuel sources (glucose & glutamine). This is typically done using ketogenic diets, fasting strategies, and metabolic drugs (like Metformin, Ivermectin, and Mebendazole).
The “Pulse” Phase: This is where therapies like HBOT, oxidative therapies, and certain chemotherapies are used to exploit the weakened cancer cells, causing oxidative stress and leading to their destruction.

When properly combined, this Press-Pulse cycle helps target both glycolytic-dependent tumours and treatment-resistant cancer stem cells (CSCs)—a key factor in preventing relapse.

HBOT for Chemotherapy Recovery & Blood Cell Support

One of the biggest challenges in conventional cancer treatment is the damage caused to healthy tissues, particularly the bone marrow, which is responsible for producing red and white blood cells.

HBOT Helps Support Blood Counts After Chemotherapy

Increases Red Blood Cell Production – HBOT stimulates the production of erythropoietin, a hormone that helps generate new red blood cells, counteracting anemia caused by chemotherapy.
Enhances White Blood Cell Function – Immune suppression is a major concern in oncology. HBOT enhances neutrophil activity and immune surveillance, helping patients recover faster.
Reduces Inflammation & Fatigue – Studies suggest that HBOT can lower systemic inflammation and improve energy levels, making it particularly helpful for patients experiencing chemo-induced fatigue.

Key Benefits of HBOT in Cancer Care

Beyond its role in metabolic oncology, HBOT provides several key benefits for cancer patients:

Reduces Side Effects of Radiation Therapy – Helps heal radiation burns, tissue necrosis, and radiation-induced fibrosis.
Supports Post-Surgical Healing – Enhances oxygen delivery to tissues, reducing surgical complications and improving wound healing.
Minimizes Nerve Damage (CIPN) – Emerging evidence suggests HBOT may help manage chemotherapy-induced peripheral neuropathy (CIPN), a common side effect of certain chemo drugs.
Improves Overall Quality of Life – Many patients report better sleep, reduced brain fog, and improved mood after consistent HBOT sessions.

What to Look for in an HBOT Provider

Not all HBOT services are created equal. When considering treatment, keep these key factors in mind:

1. Pressure Matters (2.0 – 3.0 ATA is Ideal for Oncology) - Many wellness centers offer mild hyperbaric chambers (1.3 ATA), which are not strong enough for optimal cancer support. True therapeutic HBOT occurs at 2.0 – 3.0 ATA, which ensures proper tissue oxygenation.

2. Medical Oversight - HBOT should be administered under the supervision of trained professionals who understand its role in oncology care.

3. Frequency & Duration - Most oncology protocols recommend 20-40 sessions over a period of time, depending on individual needs. As part of a press-pulse metabolic framework, back to back sessions are common in the pulse (kill) phase.

Final Thoughts: Should You Consider HBOT in Your Cancer Journey?

Hyperbaric Oxygen Therapy is a powerful adjunct to conventional and integrative cancer care. It enhances recovery, supports metabolic treatments, and helps create an internal environment less favorable to cancer survival.

If you’re undergoing cancer treatment, in recovery, or looking to optimize your long-term remission, HBOT may be worth exploring as part of a personalized, evidence-based integrative oncology plan.

Interested in learning how HBOT fits into your cancer care strategy? Book a consultation to discuss whether Hyperbaric Oxygen Therapy is right for you.

Medical Disclaimer

The information provided in this article is for educational and informational purposes only and is not intended as medical advice. It should not be used as a substitute for professional medical consultation, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider before making any decisions about your cancer treatment, including dietary changes, metabolic strategies, repurposed medications, or integrative therapies.

Every individual’s medical condition is unique, and what works for one person may not be appropriate for another. Integrating metabolic and conventional oncology approaches should be done under the supervision of a highly experienced health professional who understands the complexity of cancer care and the potential interactions between different treatments.

No guarantees of outcome are expressed or implied, and reliance on any information provided in this article is at your own discretion and risk.

References

1. Mechanisms of HBOT in Cancer Treatment:

Feldmeier, J. J., & Hampson, N. B. (2002). Hyperbaric oxygen: does it promote growth or recurrence of malignancy? Undersea & Hyperbaric Medicine, 29(1), 4-30.
Moen, I., & Stuhr, L. E. (2012). Hyperbaric oxygen therapy and cancer—a review. Targeted Oncology, 7(4), 233-242.
Daruwalla, J., & Christophi, C. (2006). Hyperbaric oxygen therapy for malignancy: a review. World Journal of Surgery, 30(12), 2112-2131.

2. HBOT Enhancing Radiotherapy:

Bennett, M. H., Feldmeier, J., Hampson, N., Smee, R., & Milross, C. (2018). Hyperbaric oxygenation for tumour sensitisation to radiotherapy. Cochrane Database of Systematic Reviews, (4).
Ogawa, K., Ishiuchi, S., Inoue, O., et al. (2003). Enhancing effect of hyperbaric oxygen therapy on radiation treatment for gliomas: a preliminary report. Journal of Neuro-Oncology, 61(2), 161-171.

3. HBOT for Radiation-Induced Tissue Injuries:

Feldmeier, J. J., & Hampson, N. B. (2002). Hyperbaric oxygen: does it promote growth or recurrence of malignancy? Undersea & Hyperbaric Medicine, 29(1), 4-30.
Spiegelberg, L., & Bennett, M. H. (2010). Hyperbaric oxygen therapy for the prevention and treatment of osteoradionecrosis: a systematic review of randomized controlled trials. Journal of Oral and Maxillofacial Surgery, 68(3), 703-712.

4. HBOT Supporting Chemotherapy Recovery:

Daruwalla, J., & Christophi, C. (2006). Hyperbaric oxygen therapy for malignancy: a review. World Journal of Surgery, 30(12), 2112-2131.
Moen, I., & Stuhr, L. E. (2012). Hyperbaric oxygen therapy and cancer—a review. Targeted Oncology, 7(4), 233-242.

5. HBOT and Immune Modulation:

Daruwalla, J., & Christophi, C. (2006). Hyperbaric oxygen therapy for malignancy: a review. World Journal of Surgery, 30(12), 2112-2131.
Moen, I., & Stuhr, L. E. (2012). Hyperbaric oxygen therapy and cancer—a review. Targeted Oncology, 7(4), 233-242.

6. HBOT in Integrative Oncology Protocols:

Moen, I., & Stuhr, L. E. (2012). Hyperbaric oxygen therapy and cancer—a review. Targeted Oncology, 7(4), 233-242.
Daruwalla, J., & Christophi, C. (2006). Hyperbaric oxygen therapy for malignancy: a review. World Journal of Surgery, 30(12), 2112-2131.

7. Safety and Contraindications of HBOT:

Feldmeier, J. J., & Hampson, N. B. (2002). Hyperbaric oxygen: does it promote growth or recurrence of malignancy? Undersea & Hyperbaric Medicine, 29(1), 4-30.
Moen, I., & Stuhr, L. E. (2012). Hyperbaric oxygen therapy and cancer—a review. Targeted Oncology, 7(4), 233-242.

Eddie Enever